Login
$XGN
$3.80 +$0.03 (0.8%) After hours

$XGN 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30%

04 Aug 2026 8-K: Results of Operations and Financial Condition

Achieved record total revenue, test volume and trailing twelve-month ASP

09 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Exagen Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting") on June 9, 2026. At the Annual Meeting, the Company's stockholders voted on three proposals, as described below. Each of the proposals was de...

11 May 2026 8-K: Results of Operations and Financial Condition

Delivers record total revenue and AVISE(R) CTD average selling price

23 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 17, 2026, Ana Hooker notified the Board of Directors (the “Board”) of Exagen Inc. (the “Company”) of her decision to resign as member of the Board, including all committees thereof, effective April 17, 2026 ("Effective Time"). M...

10 Mar 2026 8-K: Results of Operations and Financial Condition

Record full-year total revenue and AVISE® CTD average selling price

12 Jan 2026 8-K: Results of Operations and Financial Condition; Other Events

Carlsbad, CA—Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.

04 Nov 2025 8-K: Results of Operations and Financial Condition

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.

29 Jul 2025 8-K: Results of Operations and Financial Condition

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates.

17 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Eligible Directors (as defined below) on the board of directors (the “Board”) of Exagen Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compen...

11 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Exagen Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting") on June 10, 2025. At the Annual Meeting, the Company's stockholders voted on four proposals, as described below. Each of the proposals was de...

09 May 2025 8-K: Other Events

CARLSBAD, Calif., May 9, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a publi...

08 May 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Exagen Inc., a Delaware corporation (the “Company”), confirms its agreement with Canaccord Genuity LLC (“Canaccord”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also i...

05 May 2025 8-K: Results of Operations and Financial Condition

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.

28 Apr 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

[***]: THE IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THE AGREEMENT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

11 Mar 2025 8-K: Results of Operations and Financial Condition

Delivered record full-year total revenue and AVISE CTD average selling price

13 Jan 2025 8-K: Results of Operations and Financial Condition; Other Events

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

12 Nov 2024 8-K: Results of Operations and Financial Condition

Expanded AVISE® CTD trailing twelve-month average selling price

05 Aug 2024 8-K: Results of Operations and Financial Condition

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024.

02 Aug 2024 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This Employment Agreement (this “Agreement”) is effective as of September 1, 2024 (the “Effective Date”) by and between Exagen Inc. (the “Company”), a Delaware corporation, and Jeff Black (“Executive”). References below to the “Company” ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support